3-甲基-4-甲酸嘧啶 | 4021-12-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-甲基-4-甲酸嘧啶
• 中文别名: 3-甲基异烟酸；3-甲基-4-甲酸吡啶；3-甲基-吡啶-4-甲酸
• 英文名称: 3-methyl-isonicotinic acid
• 英文别名: 3-methylpyridine-4-carboxylic acid；3-methyl-4-nicotinic acid；3-Methyl-isonicotinsaeure；3-Methylisonicotinic acid
• CAS: 4021-12-9
• 化学式: C₇H₇NO₂
• mdl: MFCD00128870
• 分子量: 137.138
• InChiKey: OSMAGAVKVRGYGR-UHFFFAOYSA-N

物化性质

• 熔点：
  235℃
• 沸点：
  389℃
• 密度：
  1.230
• 闪点：
  189℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Methyl-4-pyridinecarboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Methyl-4-pyridinecarboxylic acid
CAS number: 4021-12-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7NO2
Molecular weight: 137.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲基-4-甲酸嘧啶 在 ammonium hydroxide 、 氯化亚砜 、 三氯氧磷 作用下， 以 水 为溶剂， 反应 27.0h， 生成 3-甲基-4-氰基吡啶
  参考文献：
  名称：

  通过支架跳跃策略发现和合成6,7,8,9-四氢-5 H-吡啶并[4,3 - c ] azepin-5-one新型化学型CCR2拮抗剂

  摘要：

  趋化因子CC受体亚型2（CCR2）在包括慢性炎症，糖尿病，神经性疼痛，动脉粥样硬化和癌症在内的多种治疗领域中引起了人们对药物开发的浓厚兴趣。通过采用切开-缝制的支架跳跃策略，我们确定了一个3,4-二氢-2,6-萘吡啶-1（2 H）-one的活性支架作为中心药效基团，以衍生出新颖的CCR2拮抗剂。关于环大小和萘啶酮环上取代的系统结构-活性关系研究产生了1-芳基氨基-6-烷基杂环-6,7,8,9-四氢-5 H-吡啶基[4,3- c] azepin-5-ones是具有纳摩尔抑制活性的新型CCR2拮抗剂的化学型。该化合物中最佳的拮抗活性以化合物13a为例，该化合物结合了C-1处的3,4-二氯苯氨基和N-6处的3-（4-（N-甲基甲基磺酰胺基）哌啶-1-基）丙基的最佳取代基位置，IC 50值为61 nM，CCR2的选择性是CCR5的10倍。建立了有效而通用的合成方法，以构建创新的核心结构并推导化合物集合。这是关于我们设计的6

  DOI：

  10.1016/j.bmc.2018.05.027
• 作为产物：
  描述：

  3-甲基-4-氰基吡啶 在 sodium hydroxide 作用下， 生成 3-甲基-4-甲酸嘧啶
  参考文献：
  名称：

  甲基吡啶衍生物的合成。I.4-取代的3-甲基吡啶的合成。

  摘要：

  将 3-甲基吡啶 1-氧化物与磷酰氯加热生成 4-氯-3-甲基吡啶，4-位上的氯被腈取代，然后进一步转化为羧基、乙氧基羰基或苯甲酰基。

  DOI：

  10.1248/cpb1953.5.78

文献信息

• [EN] N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS<br/>[FR] CARBOXAMIDES N-PYRAZOLYL EN TANT QU'INHIBITEURS DU CANAL CRAC
  申请人：GLAXO GROUP LTD

  公开号：WO2010122089A1

  公开（公告）日：2010-10-28

  The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

  本发明涉及酰胺化合物，其制备方法，含有这些化合物的药物组合物，以及它们在治疗过敏性疾病、炎症性疾病和免疫系统疾病等疾病、状况或障碍中的应用。
• [EN] TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRAZINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET PSYCHIATRIQUES
  申请人：LUNDBECK & CO AS H

  公开号：WO2013034755A1

  公开（公告）日：2013-03-14

  The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders.

  本发明涉及式(I)的三唑吡嗪化合物。该发明的不同方面涉及包含所述化合物的药物组合物以及将该化合物用作治疗神经系统和精神疾病的治疗剂的用途。
• [EN] ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES D'ARYLMÉTHYLÈNE UTILISÉS EN TANT QUE BLOQUEURS DES CANAUX POTASSIQUES KV1.3 DE TYPE SHAKER
  申请人：DE SHAW RES LLC

  公开号：WO2021071806A1

  公开（公告）日：2021-04-15

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

  描述了化合物的公式（I）或其药学上可接受的盐，其中取代基如本文所定义。还描述了包含相同化合物的药物组合物以及使用该药物的方法。
• Improved synthesis of sterically encumbered heteroaromatic biaryls from aromatic β-keto esters
  作者：Brandon R. Rosen、Ehesan Ul Sharif、Dillon H. Miles、Nicholas S. Chan、Manmohan R. Leleti、Jay P. Powers

  DOI：10.1016/j.tetlet.2020.151855

  日期：2020.5

  A protocol for the synthesis of hindered 4-aryl 2-aminopyrimidines from β–keto esters is described. The process employs trifluoroethanol as an essential additive to promote the guanidine condensation reaction, enabling the synthesis of 25 aryl- and heteroaryl substituted aminopyrimidines in good yields and high purities with no column chromatography. The conditions described herein are readily scalable

  描述了由β-酮酸酯合成受阻4-芳基2-氨基嘧啶的方法。该方法采用三氟乙醇作为促进胍缩合反应的必要添加剂，无需柱色谱法即可以高收率和高纯度合成25个芳基和杂芳基取代的氨基嘧啶。本文所述的条件易于扩展，并且已用于临床A 2a / A 2b R拮抗剂AB928的大规模合成。
• [EN] 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE OU PIPÉRAZINE SUBSTITUÉS PAR 1,2,4-OXADIAZOLE COMME ANTAGONISTES DE SMO
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2010013037A1

  公开（公告）日：2010-02-04

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

  本发明涉及式(I)的化合物及其药学上可接受的盐、立体异构体或互变异构体，这些化合物是Sonic Hedgehog途径的抑制剂，特别是Smo拮抗剂。因此，本发明的化合物对治疗与异常Hedgehog途径激活相关的疾病有用，包括癌症，例如基底细胞癌、髓母细胞瘤、前列腺、胰腺、乳腺、结肠、骨骼和小细胞肺癌，以及上消化道的癌症。